AbbVie (ABBV) Net Income towards Common Stockholders (2012 - 2026)

AbbVie (ABBV) has 15 years of Net Income towards Common Stockholders data on file, last reported at $697.0 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $697.0 million, down 45.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 13.37% YoY), and the FY2025 annual result was $4.2 billion, down 1.24% from the prior year.
• Net Income towards Common Stockholders slipped to $697.0 million in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $4.5 billion in Q1 2022 and troughed at -$97.0 million in Q1 2023.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders tumbled 102.79% in 2024, then surged 7991.3% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $2.5 billion in 2022, then sank by 66.67% to $824.0 million in 2023, then plunged by 102.79% to -$23.0 million in 2024, then surged by 7991.3% to $1.8 billion in 2025, then tumbled by 61.6% to $697.0 million in 2026.
• Business Quant data shows ABBV's Net Income towards Common Stockholders at $697.0 million in Q1 2026, $1.8 billion in Q4 2025, and $188.0 million in Q3 2025.